Browsing tag:

Annual Meeting

On March 11, 2014 the FDA approved Topiramate, marketed as Qudexy™ XR by Upsher-Smith Laboratories, for the treatment of partial-onset seizures (POS) or primary generalized tonic-clonic seizures in patients 10+ years of age. It is also approved as adjunctive therapy in patients 2+ years of age for the aforementioned seizures, and seizures associated with Lennox-Gastaut[…]

Read More

Over the past decade, pharmaceutical firms have been giving oncologists the choice to combine several drugs used in cancer treatment in order to battle even the most resistant of cancer cells. This move has been proven successful in some types of cancer, prompting pharmaceutical manufacturers to supply consistent, quality-controlled active pharmaceutical ingredients (API’s), such as[…]

Read More

Ramoplanin is an antibiotic glycolipodepsipeptide drug that can be used as a treatment for patients suffering with Clostridium difficile infection (CDAD infection) of the gastrointestinal tract. This drug was approved by the US Food and Drug Administration (FDA); however, this drug is considered unstable in the blood, and it degrades to inactive parts. Therefore, Ramoplanin[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service